ArticleBMC oral health2026
Open-field fluorescence guided imaging of ameloblastoma tumors in mouse patient-derived xenograft model.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe aim of our study is to use near infrared fluorescence imaging to demonstrate the localization of cetuximab-IRDye800 to ameloblastoma in vivo.
methodsAmeloblastoma tumor tissue from three patients was implanted subcutaneously into athymic nude mice to form patient-derived xenografts (PDX). Animals were randomly divided into two groups; one received the epidermal growth factor receptor (EGFR) antibody, cetuximab-IRDye800, and the other received the control antibody, IgG-IRDye800. After resection of the overlying skin, the tumors were imaged on the LUNA device, an open-field, intraoperative device. Tumor/background ratios (TBRs) were calculated and statistically analyzed using a paired t test.
resultsImaging of PDX tumors revealed the TBRs produced by cetuximab-IRDye800 (AB-20, 4.5 ± 1.57; AB-33, 1.17 ± 0.42; AB-34, 1.33 ± 0.04) were significantly higher than those produced by IgG-IRDye800 (AB-20, 2.02 ± 0.29; AB-33, 1.07 ± 0.30; AB-34, 1.11 ± 0.13; p values, AB-20, p < 0.021; AB-33; p < 0.045; AB-34; p < 0.017). Excised PDX tissues were paraffin-embedded to confirm the presence of tumor by H&E staining and EGFR expression.
conclusionFluorescently labeled anti-EGFR demonstrates specificity and sensitivity for PDX tumor xenografts using an open-field, near-infrared imaging system. These open-field devices allow real-time clinical assessment of fluorescent signals during surgery and may provide future benefit in the removal of ameloblastoma tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.